NBP.US NovaBridge Biosciences

Healthcare Biotechnology USA Stocks
0.8499 USD
Close of Nov 15, 2026
0.7718 5.19
Market cap
USD 98.6M
P/E
-
P/B
0.49x
ROE
-37.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is NBP.US undervalued?

Graham number

The Graham number of NovaBridge Biosciences cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NovaBridge Biosciences fundamental analysis

No fundamental analysis for NovaBridge Biosciences yet.

NovaBridge Biosciences stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NovaBridge Biosciences

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestina…

Full company profile